Evidence map›Paper›PMID 25025766›Full record

ArticlePloS one2014

Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.

Zhi Xu, Xinying Huo, Hua Ye, Chuanning Tang, Vijayalakshmi Nandakumar, Feng Lou, Dandan Zhang, Haichao Dong, Hong Sun, Shouwen Jiang and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Identification of early genetic changes in well-differentiated intramucosal gastric carcinoma by target deep sequencing.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019
    Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 2 institutions in 2 countries.

Zhi XuDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xinying HuoDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Hua YeSan Valley Biotechnology Incorporated, Beijing, China.
Chuanning TangSan Valley Biotechnology Incorporated, Beijing, China.
Vijayalakshmi NandakumarNorris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Feng LouSan Valley Biotechnology Incorporated, Beijing, China.
Dandan ZhangSan Valley Biotechnology Incorporated, Beijing, China.
Haichao DongSan Valley Biotechnology Incorporated, Beijing, China.
Hong SunSan Valley Biotechnology Incorporated, Beijing, China.
Shouwen JiangSan Valley Biotechnology Incorporated, Beijing, China.
Guangchun ZhangSan Valley Biotechnology Incorporated, Beijing, China.
Zhiyuan LiuSan Valley Biotechnology Incorporated, Beijing, China.
Zhishou DongSan Valley Biotechnology Incorporated, Beijing, China.
Baishuai GuoSan Valley Biotechnology Incorporated, Beijing, China.
Yan HeSan Valley Biotechnology Incorporated, Beijing, China.
Chaowei YanSan Valley Biotechnology Incorporated, Beijing, China.
Lu WangSan Valley Biotechnology Incorporated, Beijing, China.
Ziyi SuSan Valley Biotechnology Incorporated, Beijing, China.
Yangyang LiSan Valley Biotechnology Incorporated, Beijing, China.
Dongying GuDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaojing ZhangDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaomin WuDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaowei WeiDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Lingzhi HongDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yangmei ZhangDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jinsong YangDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yonglin GongDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Cuiju TangDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Lindsey JonesNorris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Xue F HuangNorris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Si-Yi ChenNorris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Jinfei ChenDepartment of Oncology, The Affiliated Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNUniversity of Southern California · US

Funding

Overcoming Immune Suppression to Enhance Tumor Vaccine EfficacyR01CA090427 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2002 to 2013
$3.1M
Developing novel adjuvants for HIV vaccinationR01AI084811 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2009 to 2013
$2.2M
NCI NIH HHS R01 CA090427NCI NIH HHS R01 CA90427NIAID NIH HHS R01 AI084811
6 · The paper itself

Abstract

Gastric cancer is the one of the major causes of cancer-related death, especially in Asia. Gastric adenocarcinoma, the most common type of gastric cancer, is heterogeneous and its incidence and cause varies widely with geographical regions, gender, ethnicity, and diet. Since unique mutations have been observed in individual human cancer samples, identification and characterization of the molecular alterations underlying individual gastric adenocarcinomas is a critical step for developing more effective, personalized therapies. Until recently, identifying genetic mutations on an individual basis by DNA sequencing remained a daunting task. Recent advances in new next-generation DNA sequencing technologies, such as the semiconductor-based Ion Torrent sequencing platform, makes DNA sequencing cheaper, faster, and more reliable. In this study, we aim to identify genetic mutations in the genes which are targeted by drugs in clinical use or are under development in individual human gastric adenocarcinoma samples using Ion Torrent sequencing. We sequenced 737 loci from 45 cancer-related genes in 238 human gastric adenocarcinoma samples using the Ion Torrent Ampliseq Cancer Panel. The sequencing analysis revealed a high occurrence of mutations along the TP53 locus (9.7%) in our sample set. Thus, this study indicates the utility of a cost and time efficient tool such as Ion Torrent sequencing to screen cancer mutations for the development of personalized cancer therapy.

Indexed as

MutationAdenocarcinomaAdultAgedAged, 80 and overDNA Mutational AnalysisExonsFemaleGenetic LociHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutation, MissenseMutation RateNeoplasm GradingTumor Suppressor Protein p53

Identifiers

PMID25025766
PMCPMC4098916
OpenAlexW2035375071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.